Free tool
FAERS Monitor: Daurismo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210656 or its brand name (Daurismo, Glasdegib Maleate). Reports on generic versions are filed under their own applications.
Reports
474
Serious
443
93% of reports
Hospitalization
227
Death reported
193
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death111
- febrile neutropenia69
- pneumonia48
- off label use34
- neoplasm progression28
- neutropenia24
- sepsis15
- toxicity to various agents13
- electrocardiogram qt prolonged12
- product use in unapproved indication11
- septic shock11
- decreased appetite10
- drug ineffective10
- infection10
- pyrexia10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 13 |
| 2019 | 116 |
| 2020 | 121 |
| 2021 | 107 |
| 2022 | 45 |
| 2023 | 20 |
| 2024 | 22 |
| 2025 | 17 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,685 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 69 | 46.2 | 37.1 | 3,013 |
| neoplasm progressionSignal | 28 | 35.8 | 25.0 | 913 |
| electrocardiogram qt prolongedSignal | 12 | 14.8 | 8.5 | 141 |
| septic shockSignal | 11 | 11.2 | 6.3 | 93 |
| neutropeniaSignal | 24 | 7.8 | 5.3 | 137 |
| pneumoniaSignal | 48 | 6.6 | 5.0 | 225 |
| sepsisSignal | 15 | 6.0 | 3.6 | 57 |
| deathSignal | 111 | 5.7 | 4.9 | 446 |
| toxicity to various agentsSignal | 13 | 3.4 | 2.0 | 20 |
| infectionSignal | 10 | 3.1 | 1.7 | 12 |
| product use in unapproved indication | 11 | 2.0 | 1.1 | 4 |
| decreased appetite | 10 | 1.9 | 1.0 | 4 |
| off label use | 34 | 1.7 | 1.2 | 10 |
| pyrexia | 10 | 1.3 | 0.7 | 0 |
| drug ineffective | 10 | 0.3 | 0.2 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.